Moleculin Biotech reports expected upcoming milestones for 2024

Moleculin Biotech announced upcoming 2024 milestones. For Annamycin in AML, 1H 2024: in-depth data review and presentation of topline data on MB-106 clinical trial; 1H 2024: MB-106 End of Phase 2 meeting with the FDA and/or its European equivalent; mid 2024: identify next phase of development/pivotal program; late 2024 into 1H 2025: initiate pivotal program. For Annamycin in STS Lung Mets: 2H 2024: final MB-107 data readout; 2024: identify next phase of development/pivotal program; late 2024 into 1H 2025: initiate 1st line STS study with an investigator-initiated trial. Moleculin is in ongoing discussions in separate programs evaluating WP1066 for the treatment of glioblastomas and/or pediatric brain tumors and expects to finalize agreements with Northwestern University for an investigator-initiated and funded trial in early 2024. Expects to report topline results from investigator-initiated Phase 1 study in pediatric brain tumors; announce results of formulation efforts for intravenous delivery; expects commencement of investigator-initiated adult clinical trial to be announced in 1H 2024. Seeking investigator-initiated pediatric cancer clinical trial in 2H 2024. Expects to report preliminary findings of animal testing of WP1096 in the Tacaribe Arenavirus and identify investigators interested in initiating a clinical trial to study the safety, pharmacokinetics, and efficacy of oral WP1122 in adult patients with GBM.